Hong Kong Stock Anomaly | Ascletis Pharma-B (01672) Surges Over 6% in Afternoon Trading on Strong ASC30 Data, Company Raises Buyback Cap to HK$500 Million

Stock News01-14

Ascletis Pharma-B (01672) experienced a surge of over 6% in afternoon trading. As of the time of writing, the stock was up 6.14%, trading at HK$13.66, with a turnover of HK$35.85 million. The movement follows the company's previous announcement of positive data from its US Phase IIa study for the oral GLP-1 drug ASC30, aimed at treating obesity. A Citigroup research report noted that this data further demonstrates ASC30's best-in-class potential and bolsters confidence in future collaborations, anticipating a positive reaction in the share price; the bank reiterated its "Buy/High Risk" rating with a target price of HK$32. Notably, Ascletis previously announced that its board believes the company's current share price is undervalued and, on December 15, resolved to increase the maximum amount for share buybacks from HK$300 million to HK$500 million, a decision based on significant progress across multiple core pipelines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment